Corrigendum to "Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer" [Eur. J. Med. Chem. 259 (2023) 115703/5].

Bo Fang Yinshuang Lai Hao Yan Yue Ma Zefeng Ni Qianqian Zhu Jianxia Zhang Yanfei Ye Mengying Wang Peipei Wang Yan Wang Shuyuan Zhang Min Hui Dalong Wang Yunjie Zhao Xiaokun Li Kun Wang Zhiguo Liu

Eur J Med Chem

Chemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, 1210 University Town, Wenzhou, Zhejiang, 325035, China; Oujiang Laboratory, Zhejiang Laboratory for Regenerative Medicine, Vision and Brain Health, Wenzhou, Zhejiang, 325035, China. Electronic address:

Published: March 2024

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.ejmech.2024.116230	DOI Listing

Publication Analysis

Top Keywords

corrigendum "design

"design synthesis

synthesis biological

biological evaluation

evaluation 16-naphthyridine-2-one

16-naphthyridine-2-one derivatives

derivatives novel

novel fgfr4

fgfr4 inhibitors

inhibitors treatment

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!